Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
MWN-AI** Summary
On February 11, 2026, Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported its financial results for the year ending December 31, 2025. The Fort Lee, New Jersey-based company, which is focused on developing innovative precision medicines in oncology, indicated that 2025 was a pivotal year, particularly with advancements in its NXP900 development program. The Phase 1b study of NXP900, targeting various tumors and a combination study with osimertinib for EGFR-mutated non-small cell lung cancer (NSCLC), is currently enrolling patients. The company is also preparing to start a combination study with lorlatinib for ALK-positive NSCLC. CEO Ron Bentsur expressed optimism, stating that with the potential of the NXP900 program, 2026 is poised to be an exciting year for the company.
Financially, Nuvectis reported a cash position of $31.6 million as of December 31, 2025, up from $18.5 million in the previous year, attributed mainly to a public offering and access to at-the-market facilities, despite rising operating expenses. The company’s net loss increased to $26.4 million from $19.0 million in 2024, which included $6.0 million in non-cash stock-based compensation and milestone-associated license fees of $2.4 million. Research and development expenses rose to $18.2 million, reflecting an increase in activity and investment in clinical studies.
Despite these losses, Nuvectis remains committed to operational execution and assures stakeholders of responsible financial management, suggesting their current cash reserves can support ongoing milestones through the later part of 2027. Overall, the company’s advancements in clinical development and financial position reflect a promising outlook as they move forward into 2026.
MWN-AI** Analysis
Nuvectis Pharma, Inc. (NASDAQ: NVCT) has made notable strides in its growth strategy as evidenced by its 2025 financial results, where cash reserves climbed to $31.6 million from $18.5 million the previous year due to successful funding initiatives. Despite a net loss increase to $26.4 million, investor confidence might be bolstered by the promising outlook of its lead candidate, NXP900, which is being evaluated in several oncology trials.
The company’s Phase 1b studies for NXP900 target critical cancer types such as non-small cell lung cancer (NSCLC), and initial patient enrollments are underway. With multiple data readouts anticipated in 2026, investor engagement could ramp up as important milestones unfold. This pipeline strength is crucial, particularly in an industry where successful drug development can substantially enhance valuations.
However, it's important to consider the increase in net loss due to higher operational costs. Research and development (R&D) expenses rose significantly, indicating robust investment in advancing the clinical portfolio, albeit it adds pressure on cash flow. With $9.4 million allocated to general and administrative expenses, investors should monitor how efficiently these funds are used in supporting commercial strategy.
Looking ahead, the current cash position is projected to sustain operations through various milestones and into the latter half of 2027, which is favorable for navigating the financial landscape. Given the anticipated developments from NXP900, Nuvectis remains a speculative yet potentially rewarding investment in biopharmaceuticals.
Investors are advised to maintain a cautious outlook, weighing the potential upside from upcoming clinical news against the backdrop of increased operational costs and the early-stage nature of its clinical trials. As always, thorough due diligence and risk assessment are critical in making informed investment decisions in this dynamic sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy study evaluating NXP900’s clinical potential in several molecularly and histologically-defined target tumors, and the combination study of NXP900 with osimertinib in patients with EGFR-mutated non-small cell lung cancer (“NSCLC”) are enrolling patients. In addition, a combination with lorlatinib in ALK-positive NSCLC, is pending commencement. With the potential embedded in the NXP900 Phase 1b program, we expect 2026 to be an exciting year for Nuvectis.”
Mr. Bentsur concluded, “We remain focused on operational execution and financial responsibility, and believe that our current cash position can take us through multiple potential NXP900 Phase 1b milestones and well into the second half of 2027.”
Full Year 2025 Financial Results
Cash and cash equivalents were $31.6 million as of December 31, 2025, compared to $18.5 million as of December 31, 2024. The increase of $13.1 million resulted from the Company's February 2025 public offering and from access to our at-the-market facility, partially offset by operating expenses.
The Company's net loss was $26.4 million for the year ended December 31, 2025, compared to $19.0 million for the year ended December 31, 2024, an increase in net loss of $7.4 million. Net loss for the 2025 fiscal year included $6.0 million in non-cash stock-based compensation and one-time license fees associated with milestone achievements of $2.4 million.
Research and development expenses, including non-cash and one-time non-recurring expenses, were $18.2 million for the year ended December 31, 2025, compared to $12.9 million for the year ended December 31, 2024, an increase of $5.3 million.
General and administrative expenses, including non-cash and one-time non-recurring expenses, were $9.4 million for the year ended December 31, 2025, compared to $6.9 million for the year ended December 31, 2024, an increase of $2.5 million.
Finance income was $1.1 million for the year ended December 31, 2025, compared to $0.8 million for the year ended December 31, 2024, an increase of $0.3 million.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company's assets include NXP900 a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study and the Phase 1b program has been initiated.
For more information on Nuvectis, please visit our website at https://nuvectis.com/.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate", "could", "estimate", "expect", "intend", "seek", "may", "might", "plan", "potential", "predict", "project", "target", "aim", "should", "will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward looking statements are based on Nuvectis Pharma, Inc.'s current expectations and interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for NXP900 and the timing and safety and efficacy data expectations for the monotherapy and combination components of the NXP900 Phase 1b program and estimates and projections regarding our financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled "Risk Factors" in our 2025 Form 10-K and our other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
| NUVECTIS PHARMA, INC. | |||||||
| BALANCE SHEETS | |||||||
| (USD in thousands, except per share and share amounts) | |||||||
| December 31, | |||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| CURRENT ASSETS | |||||||
| Cash and cash equivalents | $ | 31,634 | $ | 18,533 | |||
| Other current assets | 75 | 74 | |||||
| TOTAL CURRENT ASSETS | 31,709 | 18,607 | |||||
| TOTAL ASSETS | $ | 31,709 | $ | 18,607 | |||
| Liabilities and Shareholders’ Equity | |||||||
| CURRENT LIABILITIES | |||||||
| Accounts payables | $ | 6,274 | $ | 2,498 | |||
| Accrued liabilities | 115 | 840 | |||||
| Employee compensation and benefits | 6,907 | 5,556 | |||||
| TOTAL CURRENT LIABILITIES | 13,296 | 8,894 | |||||
| TOTAL LIABILITIES | 13,296 | 8,894 | |||||
| COMMITMENTS AND CONTINGENCIES, see Note 3 | |||||||
| SHAREHOLDERS’ EQUITY, see Note 6 | |||||||
| Common Shares, $0.00001 par value – 60,000,000 shares authorized as of December 31, 2025, and December 31, 2024, 25,676,798, and 19,495,683 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | * | * | |||||
| Additional paid in capital | 118,100 | 82,958 | |||||
| Accumulated deficit | (99,687 | ) | (73,245 | ) | |||
| TOTAL SHAREHOLDERS’ EQUITY | 18,413 | 9,713 | |||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 31,709 | $ | 18,607 | |||
| * Represent amount lower than $1,000 USD. | |||||||
| NUVECTIS PHARMA, INC. | |||||||
| STATEMENT OF OPERATIONS | |||||||
| (USD in thousands, except per share and share amounts) | |||||||
| For the year ended | For the year ended | ||||||
| December 31, 2025 | December 31, 2024 | ||||||
| OPERATING EXPENSES | |||||||
| Research and development | $ | 18,153 | $ | 12,918 | |||
| General and administrative | 9,421 | 6,929 | |||||
| OPERATING LOSS | (27,574 | ) | (19,847 | ) | |||
| Finance income | 1,132 | 847 | |||||
| NET LOSS | $ | (26,442 | ) | $ | (19,000 | ) | |
| EFFECT OF WARRANTS MODIFICATION, | (2,429 | ) | — | ||||
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | (28,871 | ) | (19,000 | ) | |||
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING | $ | (1.32 | ) | $ | (1.11 | ) | |
| Basic and diluted weighted average number of common shares outstanding | 21,812,716 | 17,113,169 |
FAQ**
What are the key milestones expected for Nuvectis Pharma Inc. NVCT in the NXP900 Phase development program during 2026, and how do these milestones impact the company’s financial performance?
Given the increase in net loss for Nuvectis Pharma Inc. NVCT from $19 million in 20to $26.4 million in 2025, what measures are being taken to manage operating expenses while advancing clinical trials?
How does Nuvectis Pharma Inc. NVCT plan to utilize its current cash position of $31.6 million to efficiently fund multiple potential NXP900 Phase 1b milestones through to the second half of 2027?
Can you elaborate on the potential therapeutic impacts of NXP900 and how Nuvectis Pharma Inc. NVCT intends to differentiate it from existing treatment options in the oncology market?
**MWN-AI FAQ is based on asking OpenAI questions about Nuvectis Pharma Inc. (NASDAQ: NVCT).
NASDAQ: NVCT
NVCT Trading
-0.78% G/L:
$8.955 Last:
47,256 Volume:
$8.91 Open:
